LAVAL, Que. | Actelion Pharmaceuticals Canada has announced that a pivotal study with macitentan in patients with pulmonary arterial hypertension (PAH) has demonstrated a significant reduction in morbidity and mortality.
Check out our review of recent healthcare stories in the media - Top Story: Private hospital will provide care to aboriginal people across Canada. Read this and